Trial continues after patient death: French heartmaker

French biomedical firm Carmat said Tuesday it would implant its experimental artificial heart into another three people, as planned, after the first recipient died.

In an email to AFP, the company said it was too soon to draw conclusions about the device's efficacy.

A 76-year-old recipient died over the weekend, 75 days after receiving the gadget, whose trials are being closely followed by French investors.

"It is premature to draw conclusions based on the outcomes from a single patient," said the the firm, whose stock was suspended at its own request on Tuesday.

"Carmat does not intend announcing the results of this trial until the implants and 30-day followup of all four intended four patients are complete."

The septuagenarian with terminal was one of four people, all with end-stage , selected for the experiment.

The trial would be considered a success if each of the four survive for at least a month.

Artificial hearts have been in use for many years as a temporary fix for patients with chronic heart problems.

Unlike these mostly synthetic pumps, the Carmat product aims to provide a longer-term solution—up to five years—to bridge the wait for a and enabling hospitalised patients to go back home and even resume work.

The device, a self-contained unit implanted in a patient's chest, is a mix of synthetic materials and animal tissue, and seeks to mimic the form and function of an actual human .

Nearly 100,000 people in Europe and the United States are in need of a , according to Carmat.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Poor response to cholesterol drugs may indicate blocked arteries

9 hours ago

If your "bad" cholesterol level stays the same or increases after you take statin drugs, you may have more blocked arteries than people whose levels drop, according to research in the American Heart Association journal Arteriosclerosis, Th ...

Review: more whole grains, less coronary heart disease

Feb 25, 2015

(HealthDay)—Higher dietary intake of whole grains may reduce the risk of coronary heart disease (CHD), according to a meta-analysis published in the March 1 issue of The American Journal of Cardiology.

Shining new light on vascular diseases in diabetics

Feb 25, 2015

Approximately 8 to 12 million people in the United States alone are suffering from peripheral arterial disease (PAD), a common vascular problem that is caused by narrowing of the arteries as a result of plaque ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.